top of page

Selected Publications


Nguyen BT et al. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection. PLoS Biology 2023.

Lingas G et al. Neutralizing Antibody Levels as a Correlate of Protection Against SARS-CoV-2 Infection: A Modeling Analysis. Clinical Pharmacology and Therapeutics 2023.

Kerioui M et al. Nonlinear multilevel joint model for individual lesion kinetics and survival to characterize intra-individual heterogeneity in patients with advanced cancer. Biometrics 2023.

Clairon Q et al. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. PLoS Computational Biology 2023.

Marc A et al. Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates. PLoS Computational Biology 2023.



Mitja O et al. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain. The Lancet Infectious Diseases 2022.

El Messaoudi S et al. A semi-mechanistic model to characterize the long-term dynamic of HBV markers during treatment with lamivudine and Peg-IFN. Clinical Pharmacology and Therapeutics 2022.

Marlin R et al. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nature communications 2022.

Delattre R et al. Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy. Cell Reports 2022.

Lingas G et al. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modeling analysis of the randomized, controlled, open-label DisCoVeRy trial. Journal of Antimicrobial Chemotherapy 2022.



Marc A et al. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Elife 2021.

Maisonnasse P et al. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications 2021.

Gonçalves A et al. SARS-CoV-2 viral dynamics in non-human primates. PLoS Computational Biology 2021.


Néant et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients: results from the French Covid-19 cohort. PNAS 2021.


​​Czuppon P et al. Success of prophylactic antiviral therapy for SARS-CoV-2: predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Computational Biology 2021.


Lingas G et al. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PLoS Computational Biology 2020.

Gonçalves A et al. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. Clinical Pharmacology & Therapeutics: PSP 2020.

Maisonnasse P et al. Hydroxychloroquine against SARS-CoV-2 infection in non-human primates. Nature 2020.

Kerioui M et al. Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modelling in the context of cancer immunotherapy. Statistics in Medicine 2020.


Madelain V et al. Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials. CPT:PSP 2019.

Tardivon C et al . Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow-up. Clinical Pharmacology & Therapeutics 2019; 106: 810-820.


Madelain V et al. Ebola viral dynamics in nonhuman primates: insights into virus immuno-pathogenesis and antiviral strategies. Nature Communications 2018; 9: 4013

Guedj J et al. Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Medicine 2018; 15(3): e1002535.



Nguyen THT et al. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Scientific Report 2017; 7: e10233.

Best K et al. Zika plasma viral dynamics in non-human primates: insights into early infection and antiviral strategies. PNAS 2017; 114(33): 8847-8852.

Madelain V et al. Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies of haemorrhagic fever viruses. Antimicrobial Agents & Chemotherapy 2017; 61:e01305-16

bottom of page